<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00524745</url>
  </required_header>
  <id_info>
    <org_study_id>HPV01</org_study_id>
    <nct_id>NCT00524745</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil</brief_title>
  <official_title>Comparison of the Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil Vaccine to Prevent HPV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Hygiene and Epidemiology, Vietnam</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that Gardasil速 vaccine, when given to girls 11-13 years of age according to 1
      of 3 alternative 3-dose schedules (0, 3, 9 months; 0, 6, 12 months; or 0, 12, 24 months),
      results in anti-HPV type 16 and anti-HPV type 18 responses 28 days post-dose 3 that are
      similar to those obtained when the vaccine is given on the standard 3-dose schedule of 0, 2,
      6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary objective:

      To test the hypothesis that Gardasil速 vaccine, when administered to girls 11-13 years of age
      according to 1 of 3 alternative 3-dose schedules (0,3,9 months; 0,6,12 months; or 0,12,24
      months), results in anti-HPV 16 and anti-HPV 18 responses 28 days post-dose 3 that are
      similar to those obtained when the vaccine is administered on the standard 3-dose schedule of
      0,2,6 months.

      Secondary objectives:

        1. To test the hypothesis that Gardasil速 vaccine, when administered to girls 11-13 years of
           age according to 1 of 3 alternative 3-dose schedules (0,3,9 months; 0,6,12 months; or
           0,12,24 months), results in anti-HPV 6 and anti-HPV 11 responses 28 days post-dose 3
           that are similar to those obtained when the vaccine is administered on the standard
           3-dose schedule of 0,2,6 months.

        2. To describe the safety profile of the administration of Gardasil速 according to each of
           the four schedules by assessing:

           (i) immediate reactogenicity (reactions within 30 minutes after each injection); (ii)
           solicited (local reactogenicity and fever) and unsolicited events occurring during the
           first 7 days following each vaccination; (iii) serious adverse events occurring up to
           one month following the last dose of vaccine; (iv) deaths or adverse events occurring at
           any time determined to be vaccination-related.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of Antibody Response to HPV Type 16 1 Month Post-dose 3 for Each Alternative Schedule Compared to the Standard Schedule.</measure>
    <time_frame>25 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of Antibody Response to HPV Type 18 1 Month Post-dose 3 for Each Alternative Schedule Compared to the Standard Schedule.</measure>
    <time_frame>25 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of Antibody Response to HPV Type 6 1 Month Post-dose 3 for Each Alternative Schedule Compared to the Standard Schedule.</measure>
    <time_frame>25 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Antibody Response to HPV Type 11 1 Month Post-dose 3 for Each Alternative Schedule Compared to the Standard Schedule.</measure>
    <time_frame>25 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">903</enrollment>
  <condition>Dose Schedule Study</condition>
  <arm_group>
    <arm_group_label>0,2,6 month vaccination schedule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0,3,9 month vaccination schedule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0,6,12 month vaccination schedule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0,12,24 month vaccination schedule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine</intervention_name>
    <description>Three doses of quadrivalent HPV recombinant vaccine administered at different dosing intervals in each of four study arms.</description>
    <arm_group_label>0,2,6 month vaccination schedule</arm_group_label>
    <arm_group_label>0,3,9 month vaccination schedule</arm_group_label>
    <arm_group_label>0,6,12 month vaccination schedule</arm_group_label>
    <arm_group_label>0,12,24 month vaccination schedule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 11-13 years of age.

          2. Signed informed consent form (both parent's &amp; daughter's signature).

          3. Good health status.

          4. Able to comply with trial protocol.

          5. Plans to stay at current school for duration of study.

        Exclusion Criteria:

          1. Prior HPV vaccination

          2. Pregnant or lactating or intends to become pregnant during study period.

          3. Apparent moderate or severe acute illness.

          4. Clinical history of bleeding disorder such as hemophilia, thrombocytopenia, or
             anticoagulant therapy.

          5. Clinical history of impaired immune responsiveness, whether due to use of
             immunosuppressive therapy, a genetic defect, HIV infection, or other causes.

          6. Hypersensitivity to the active substances or to any of the excipients of the HPV
             vaccine, or such reactions to other vaccines received in the past.

          7. Investigational drug or investigational vaccine administered during the period from 30
             days before to 30 days after any dose of HPV vaccine.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathy Neuzil, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>PATH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute of Hygiene and Epidemiology</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <results_reference>
    <citation>Neuzil KM, Canh DG, Thiem VD, Janmohamed A, Huong VM, Tang Y, Diep NT, Tsu V, LaMontagne DS. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA. 2011 Apr 13;305(14):1424-31. doi: 10.1001/jama.2011.407.</citation>
    <PMID>21486975</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2007</study_first_submitted>
  <study_first_submitted_qc>September 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2007</study_first_posted>
  <results_first_submitted>August 3, 2011</results_first_submitted>
  <results_first_submitted_qc>August 3, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 8, 2011</results_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gardasil</keyword>
  <keyword>Human Papillomavirus</keyword>
  <keyword>HPV vaccine</keyword>
  <keyword>Cervical cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>21 schools were (1) matched according to size, urban/rural location and ethnicity; (2) assigned to one of four groups; and (3) randomized to one of four schedules
All girls 11-13 years of age in these schools were eligible to participate.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>0,3,9 Month Schedule</title>
        </group>
        <group group_id="P2">
          <title>0,6,12 Month Schedule</title>
        </group>
        <group group_id="P3">
          <title>0,12,24 Month Schedule</title>
        </group>
        <group group_id="P4">
          <title>Standard (0,2,6 Month) Schedule</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="229"/>
                <participants group_id="P2" count="206"/>
                <participants group_id="P3" count="241"/>
                <participants group_id="P4" count="227"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="195"/>
                <participants group_id="P2" count="193"/>
                <participants group_id="P3" count="212"/>
                <participants group_id="P4" count="205"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>subject withdrawal or lost to follow up</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0,3,9 Month Schedule</title>
        </group>
        <group group_id="B2">
          <title>0,6,12 Month Schedule</title>
        </group>
        <group group_id="B3">
          <title>0,12,24 Month Schedule</title>
        </group>
        <group group_id="B4">
          <title>Standard (0,2,6 Month) Schedule</title>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="229"/>
            <count group_id="B2" value="206"/>
            <count group_id="B3" value="241"/>
            <count group_id="B4" value="227"/>
            <count group_id="B5" value="903"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                    <measurement group_id="B2" value="206"/>
                    <measurement group_id="B3" value="241"/>
                    <measurement group_id="B4" value="227"/>
                    <measurement group_id="B5" value="903"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                    <measurement group_id="B2" value="206"/>
                    <measurement group_id="B3" value="241"/>
                    <measurement group_id="B4" value="227"/>
                    <measurement group_id="B5" value="903"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Vietnam</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                    <measurement group_id="B2" value="206"/>
                    <measurement group_id="B3" value="241"/>
                    <measurement group_id="B4" value="227"/>
                    <measurement group_id="B5" value="903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Antibody Response to HPV Type 16 1 Month Post-dose 3 for Each Alternative Schedule Compared to the Standard Schedule.</title>
        <time_frame>25 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0,3,9 Month Schedule</title>
          </group>
          <group group_id="O2">
            <title>0,6,12 Month Schedule</title>
          </group>
          <group group_id="O3">
            <title>0,12,24 Month Schedule</title>
          </group>
          <group group_id="O4">
            <title>Standard (0,2,6 Month) Schedule</title>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Antibody Response to HPV Type 16 1 Month Post-dose 3 for Each Alternative Schedule Compared to the Standard Schedule.</title>
          <units>GMT ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="193"/>
                <count group_id="O3" value="212"/>
                <count group_id="O4" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" lower_limit="0.71" upper_limit="1.21"/>
                    <measurement group_id="O2" value="0.99" lower_limit="0.75" upper_limit="1.30"/>
                    <measurement group_id="O3" value="0.63" lower_limit="0.48" upper_limit="0.83"/>
                    <measurement group_id="O4" value="1.0">Standard schedule is the comparator for the GMT ratio outcome reported.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Antibody Response to HPV Type 18 1 Month Post-dose 3 for Each Alternative Schedule Compared to the Standard Schedule.</title>
        <time_frame>25 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0,3,9 Month Schedule</title>
          </group>
          <group group_id="O2">
            <title>0,6,12 Month Schedule</title>
          </group>
          <group group_id="O3">
            <title>0,12,24 Month Schedule</title>
          </group>
          <group group_id="O4">
            <title>Standard (0,2,6 Month) Schedule</title>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Antibody Response to HPV Type 18 1 Month Post-dose 3 for Each Alternative Schedule Compared to the Standard Schedule.</title>
          <units>GMT ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="193"/>
                <count group_id="O3" value="213"/>
                <count group_id="O4" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.69" upper_limit="1.12"/>
                    <measurement group_id="O2" value="0.92" lower_limit="0.71" upper_limit="1.18"/>
                    <measurement group_id="O3" value="0.77" lower_limit="0.62" upper_limit="0.96"/>
                    <measurement group_id="O4" value="1.0">Standard schedule is the comparator for the GMT ratio outcome reported.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Antibody Response to HPV Type 6 1 Month Post-dose 3 for Each Alternative Schedule Compared to the Standard Schedule.</title>
        <time_frame>25 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0,3,9 Month Schedule</title>
          </group>
          <group group_id="O2">
            <title>0,6,12 Month Schedule</title>
          </group>
          <group group_id="O3">
            <title>0,12,24 Month Schedule</title>
          </group>
          <group group_id="O4">
            <title>Standard (0,2,6 Month) Schedule</title>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Antibody Response to HPV Type 6 1 Month Post-dose 3 for Each Alternative Schedule Compared to the Standard Schedule.</title>
          <units>GMT ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="191"/>
                <count group_id="O3" value="207"/>
                <count group_id="O4" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" lower_limit="0.80" upper_limit="1.44"/>
                    <measurement group_id="O2" value="1.14" lower_limit="0.85" upper_limit="1.52"/>
                    <measurement group_id="O3" value="0.64" lower_limit="0.46" upper_limit="0.90"/>
                    <measurement group_id="O4" value="1.0">Standard schedule is the comparator for the GMT ratio outcome reported.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Antibody Response to HPV Type 11 1 Month Post-dose 3 for Each Alternative Schedule Compared to the Standard Schedule.</title>
        <time_frame>25 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0,3,9 Month Schedule</title>
          </group>
          <group group_id="O2">
            <title>0,6,12 Month Schedule</title>
          </group>
          <group group_id="O3">
            <title>0,12,24 Month Schedule</title>
          </group>
          <group group_id="O4">
            <title>Standard (0,2,6 Month) Schedule</title>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Antibody Response to HPV Type 11 1 Month Post-dose 3 for Each Alternative Schedule Compared to the Standard Schedule.</title>
          <units>GMT ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="193"/>
                <count group_id="O3" value="212"/>
                <count group_id="O4" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" lower_limit="0.70" upper_limit="1.06"/>
                    <measurement group_id="O2" value="0.86" lower_limit="0.69" upper_limit="1.06"/>
                    <measurement group_id="O3" value="0.96" lower_limit="0.80" upper_limit="1.15"/>
                    <measurement group_id="O4" value="1.0">Standard schedule is the comparator for the GMT ratio outcome reported.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited local reactions within 7 days post-vacciantion</time_frame>
      <group_list>
        <group group_id="E1">
          <title>0,3,9 Month Schedule</title>
        </group>
        <group group_id="E2">
          <title>0,6,12 Month Schedule</title>
        </group>
        <group group_id="E3">
          <title>0,12,24 Month Schedule</title>
        </group>
        <group group_id="E4">
          <title>Standard (0,2,6 Month) Schedule</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="148" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="131" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever post dose 1</sub_title>
                <description>7-day subject diary</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Fever post dose 2</sub_title>
                <description>7-day subject diary</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Fever post-dose 3</sub_title>
                <description>7 day subject diary</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pain at injection site post dose 1</sub_title>
                <description>7 day subject diary</description>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="114" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="120" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pain at injection site post dose 2</sub_title>
                <description>7 day subject diary</description>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="124" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="134" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="117" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pain at injection site post dose 3</sub_title>
                <description>7 day subject diary</description>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="139" subjects_at_risk="240"/>
                <counts group_id="E4" subjects_affected="121" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathleen Neuzil, Principal Investigator</name_or_title>
      <organization>PATH</organization>
      <phone>206-285-3500 ext 4864</phone>
      <email>kneuzil@path.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

